Dr. Emmanuel Dulac joined Alnylam in August 2016 and is responsible for establishing the Alnylam global commercial footprint. He leads the development of the global commercial organization, building global commercial capabilities, including support of patients post product launch and building the US commercial operations.
Emmanuel brings more than 20 years of international experience to Alnylam in the biotech and pharmaceutical industry. He joins the company from Shire where he was Senior Vice President, Head of the Rare Disease Business Unit. In this function, Emmanuel led the growth of a portfolio of five global brands worth $500 million and developed an innovative patient service hub. Prior to Shire, Emmanuel held various roles of increasing responsibility at Sanofi, Abbott, and Novartis in global, regional and local functions.
Emmanuel graduated from the University of Paris XI with a Doctorate in Pharmacology (PharmD, PhD) and completed an MBA degree from the ESSEC School in Paris.